-
Amgen (NasdaqGS:AMGN) reported new Phase 3 data for dazodalibep in Sjögren's disease at ACR Convergence 2026.
-
The company shared long term safety and efficacy data for UPLIZNA in IgG4-related disease and additional rare autoimmune conditions.
-
Management also announced a diagnostic collaboration with the National Organization for Rare Disorders focused on earlier identification of rare diseases.
-
These dazodalibep and UPLIZNA updates only capture part of what Amgen's rare disease shift could mean for investors. Our analysis turns up 1 warning sign for Amgen as well.
For a broader view on where rare disease research and data heavy medicine might be heading next, see the wider trend through 34 healthcare AI stocks .
Amgen is a large US biopharma group with a US$240.4b market cap that focuses on human therapeutics. Deeper work in rare autoimmune diseases and diagnostic partnerships directly tie into how its drug discovery engine and commercial footprint could evolve from here.
4 things going right for Amgen that this headline doesn't cover.
Rare disease push supports Amgen's multi-franchise Narrative, but commercial depth is still an open question
For Amgen, the dazodalibep Sjögren's data and deeper UPLIZNA experience line up squarely with the Narrative that future growth rests on a broader mix of franchises instead of a few aging blockbusters. The new autoimmune readouts, together with the NORD diagnostic collaboration, speak directly to the rare disease catalyst already flagged around UPLIZNA and dazodalibep and the goal of building durable autoimmune revenue streams. The Board's decision to affirm a US$2.52 per share quarterly dividend at the same time also reinforces the picture of a business comfortable funding both research and shareholder returns from current cash flows.
See how these catalysts shape Amgen's path to a $391 fair value .
For this story to move from scientific momentum to financial impact, the key checks are regulatory and uptake related. Investors will likely focus on whether the OASIZ 303 trial for dazodalibep in high symptom Sjögren's hits its endpoints when it reads out in Q4 2026, and then on any subsequent regulatory filings and early prescription trends in Sjögren's and IgG4 related disease if approvals follow.
Add Amgen to your Watchlist and get alerts as these catalysts play out.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMGN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
